12 chapters across the catalog
New medical research suggests that GLP-1 receptor agonists, commonly used for weight loss and diabetes, may reduce the risk of erectile dysfunction. The hosts view this as the final stage of a massive marketing campaign for the drugs, which have already been linked to reduced risks for heart attacks, alcoholism, and smoking.
Ozempic Price War, Side Effects, Dr. Celine Gounder
Novo Nordisk is cutting the price of Ozempic to compete with Eli Lilly's weight loss drugs, Monjaro and ZepBound. Dr. Celine Gounder discusses the "price war" and the effectiveness of these medications. A new side effect dubbed "Ozempic vulva," involving loose skin in the vaginal area, is highlighted as a consequence of rapid weight loss.
Recent reports in The Atlantic suggest that the science behind Ozempic and other GLP-1 drugs may be misunderstood, as the weight-loss effects appear to be driven by the brain rather than the gut. These drugs cross the blood-brain barrier and may affect addictive behaviors, though scientists admit they do not fully understand the long-term consequences. Despite this, prescriptions have increased 400% since 2019, with the industry projected to reach $100 billion by 2030.
Ozempic Studied as a Treatment for Alcohol Addiction
A study at the CU Anschutz Medical Campus is investigating whether the weight-loss drug Ozempic can reduce the desire for alcohol. Researchers hope the drug could represent a "Prozac moment" for addiction treatment, potentially curbing smoking and illicit drug use as well.
Eli Lilly Zepbound Pricing, Pharmaceutical Margins
Eli Lilly announced it will sell its weight loss drug Zepbound directly to consumers for half the retail price if their insurance does not cover it. The hosts point out that the company still profits at this lower price, highlighting the extreme markups typically charged to insurance providers and Medicare.
Fen-Phen History and FDA Approval of Ozempic for Heart Disease
The history of the 1990s weight loss drug Fen-Phen is recalled as a cautionary tale for current GLP-1 users, noting the heart damage and lawsuits that followed its popularity. Meanwhile, the FDA has approved Ozempic for the reduction of heart disease risk, a move that ensures insurance companies must cover the expensive medication. Critics argue this is a strategy to entrench the drug in government-funded healthcare packages.
The hosts open the broadcast from FEMA Region 6 and Northern Silicon Valley. They discuss observations regarding Megyn Kelly's appearance, specifically attributing it to "Ozempic face." A critique follows regarding the United States media apparatus and its perceived control by pharmaceutical companies.
Mounjaro vs. Ozempic and the Medicare Coverage Push
A report comparing Mounjaro and Ozempic identifies Mounjaro as the "clear winner" for weight loss. The hosts argue that the pharmaceutical industry is lobbying for Medicare to cover these expensive drugs by reclassifying obesity as a disease, which would force private insurers to follow suit and create a massive taxpayer-funded revenue stream.
Pharmaceutical Marketing for Menopause and Perimenopause
The hosts critique a news segment featuring Dr. Alicia Robbins, who suggests that women in their 40s should use weight loss drugs to manage perimenopause symptoms. They characterize this as "ghoulish" marketing intended to expand the consumer base for GLP-1 drugs to younger, healthy populations.
Reports of gastroparesis, or stomach paralysis, have emerged among users of weight loss drugs like Ozempic and Wegovy. Dr. Darien Sutton explained that while these medications work by slowing gastric emptying, some patients experience severe complications requiring hospitalization. Despite these reports, medical contributors maintain that larger studies have not yet proven a definitive cause-and-effect relationship beyond the general population.
The American Academy of Pediatrics (AAP) issued new guidelines recommending aggressive early intervention for childhood obesity, including weight loss medications and bariatric surgery for children as young as 12 and 13. Critics argue that these recommendations ignore the role of highly processed foods and the "food pyramid" in the obesity crisis. The rise of drugs like Ozempic is highlighted as part of a growing pharmaceutical trend to treat obesity as a chronic disease rather than a dietary issue.
The herbal stimulant khat, common in Yemen and East Africa, is discussed regarding its legal status and potential as a weight-loss aid. A client of a prominent attorney reportedly served a year in jail for possessing 40 pounds of the substance, which is classified as a Schedule 1 drug in the U.S.
